type 2 diabetes
Conditions
Interventions
GLP-1 analogue therapy: Liraglutide should be initiated with a dose of 0.3mg once daily and increased by 0.3 mg increments at interval of at least one week. The dosage should be appropriately adjus
s condition
upper limit is 0.9mg.
Insulin therapy: The fine contents of medical treatment are not asked.
Sponsors
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with type 2 diabetes (6.2%<= HbA1c(NGSP)) taking with several OADs for more than 3 month treatments. 2.Patients with diabetic nephropathy.(30-1500 mg/g Cre) 3.Patients with the age between 20-75 years old 4.Sex: Unquestioned 5.Patients who agreed with the participation in this study with written consent
Exclusion criteria
Exclusion criteria: 1. Diabetic coma, diabetic ketoacidosis and type 1 patients 2.Patients with the severe renal impairment.(Serum creatinine >=3.0mg/dl) 3.Patients with liver disfunction(ALT surpasses 3 times of normal upper limit) 4.Patient who has digestive trouble 5. In emergency cases such as severe infection and surgery 6.Patients with a history of lactic acidosis and pancreatitis 7.The patient who has the state of being easy to be accompanied by the patient and hypoxemia which have an advanced obstacle in cardiovascular systems, such as a shock, heart failure, myocardial infarction, and pulmonary embolism, and a pulmonary function. 8.Patient Who Has Dehydration 9.Alcoholic Excessive Ingestion Patient 10.Patient of Poor Nutritional Status, Starvation, Debility State, Hypophysis Malfunction, or Adrenal-Function Insufficiency 11.Pregnant Woman or Woman that May Have Become Pregnant 12.Insulin Preparation, GLP-1 Receptor Operation Medicine, Patient under DPP-4 Inhibitor Prescription 13.Patient Who Has Anamnesis of Hypersensitivity to Medicine of Ingredient of Research Medicine, or the Same Action Mechanism of the Research Medicine 14.Patient Whom Family Doctor Made Unsuitable to Research Participation from Medical Rationale
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate and amount of change of urinary microalbumin in the three-month average of 10, 11, and 12 months after from the start of treatment. | — |
Countries
Japan
Contacts
Public ContactEiichi Hayashida
Graduate School of Medical Sciences, Kyushu University Department of Medicine and Bioregulatory Science
Outcome results
None listed